Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd has announced substantial progress in their dengue fever drug trial, with the US FDA clearing protocol amendments for their Phase 2a/b clinical study, now named PROTECT. The trial features both prophylactic and therapeutic arms, set to begin dosing in late September with a full readout expected by year-end. Moreover, the company has managed to slash trial costs to around US$1.08m, thanks to a grant and internal streamlining of operations.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
